EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.
about
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report.Functional disruption of the Golgi apparatus protein ARF1 sensitizes MDA-MB-231 breast cancer cells to the antitumor drugs Actinomycin D and Vinblastine through ERK and AKT signaling.Q58736062Characteristics and outcome of patients with newly diagnosed advanced or metastatic lung cancer admitted to intensive care units (ICUs)
P2860
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
EGFR TKI as first-line treatme ...... ve non-small-cell lung cancer.
@en
EGFR TKI as first-line treatme ...... ve non-small-cell lung cancer.
@nl
type
label
EGFR TKI as first-line treatme ...... ve non-small-cell lung cancer.
@en
EGFR TKI as first-line treatme ...... ve non-small-cell lung cancer.
@nl
prefLabel
EGFR TKI as first-line treatme ...... ve non-small-cell lung cancer.
@en
EGFR TKI as first-line treatme ...... ve non-small-cell lung cancer.
@nl
P2093
P2860
P356
P1433
P1476
EGFR TKI as first-line treatme ...... ve non-small-cell lung cancer.
@en
P2093
P2860
P304
75712-75726
P356
10.18632/ONCOTARGET.20095
P407
P577
2017-08-09T00:00:00Z